Back to Agenda
Updating Ethics: What’s New (and why it Matters!) in the 2024 Declaration of Helsinki Revision
Session Chair(s)
Melissa Heidelberg, MS
Director, Global Bioethics and Technology Ethics Lead
Takeda, United States
This session will review the 2024 revision of the Declaration of Helsinki, one of the foundational codes of clinical research ethics, and the rationale and practical implications of the changes made in the current version.
Learning Objective : Discuss the history of the Declaration of Helsinki and its relevance and importance for the healthcare industry; Recognize the changes made in the 2024 version and how they will impact the conduct of biopharma clinical trials; Discuss multi-stakeholder efforts that are working towards operationalizing ethical principles in the DOH and where more collaboration and alignment is needed.
Speaker(s)
Panelist
Shari Targum, MD, MPH, FACC, FACP
FDA, United States
Acting Director, Office of Clinical Policy, Office of the Commissioner
Speaker
Karla Childers, MS
Johnson & Johnson, United States
Vice President, Bioethics, Policy & Partnerships
Have an account?